

PHARMANUTRA: 2017 PRELIMINARY RESULTS DOUBLE-DIGIT REVENUE AND MARGIN GROWTH

Pisa, February 22, 2018 - [PharmaNutra](#) (Aim Italia - Ticker PHN), a mouth-dispersible iron product nutraceutical sector leader, announces the preliminary revenue and EBITDA results for 2017. The full results shall be communicated following the Board of Directors meeting called to approve the 2017 Financial Statements on March 20, 2018.

2017 Revenues

For 2017 the PharmaNutra Group reports **consolidated revenues of Euro 37.8 million**, up 14.5% on the previous year. This result was achieved thanks to the consolidation of competitive advantages on the Italian market - in particular through significant revenue growth for the Sideral and Cetilar brand products - in addition to a strengthened international presence as the company enters new markets.

2017 EBITDA

Pharmanutra Group **EBITDA** reports **over 26% growth on the previous year**, due - in addition to that of the parent company Pharmanutra Spa - improved margins for the subsidiaries Junia Pharma Srl and Alesco Srl.

2017 EBITDA Margin

The Group expects an EBITDA margin on revenues of over 25%, up over 2% on the previous year (22.8% in 2016).

Andrea Lacorte, Chairman of Pharmanutra, stated: *“With great pride, we communicate these extremely positive results to our shareholders, indicating ongoing and double-digit growth for the Group. This follows PharmaNutra’s further strengthening internationally, with the entry into new markets and as a direct consequence of research and development which has always been a strategic innovation asset for the Group and upon which we will continue to focus in order to create innovative products with unique features”.*

PharmaNutra S.p.A.

Founded and led by Chairman Andrea Lacorte and Vice Chairman Roberto Lacorte, PharmaNutra is a Pisa-based enterprise created in 2003 to develop nutraceutical products and innovative medical devices. Representing Italian pharma excellence, the company is present in 38 countries, has 50 direct employees, of which 9 researchers, and a network of 150 single-mandate sales representatives and collaborates with, among others, the Universities of Pisa, Milan, Brescia, Modena, Verona, Barcelona and Brisbane. PharmaNutra is the European mouth-dispersible iron supplement leader with the patented SiderAL product, which in Italy has a 50% market share of the OTC oral iron market. Cetilar was launched on the market in 2017, a formula entirely patented and produced by PharmaNutra, testament to the high quality scientific research undertaken by the Tuscan enterprise. <http://www.PharmaNutra.it>

For further information:

PharmaNutra S.p.A.

Via Delle Lenze, 216/b
56122 Pisa
Tel. +39 050 7846500
Fax +39 050 7846524
investorrelation@PharmaNutra.it

Nomad & Specialist

CFO SIM S.p.A.
Via dell'Annunciata 23/4
20121 Milan
Tel. +39 02 303431
ecm@cfosim.com

Press Office

Spriano Communication&Partners

Tel. +39 02 83635708
Matteo Russo - Cristina Tronconi
Mob. +39 347 9834881 +39 346 0477901
mrusso@sprianocommunication.com
ctronconi@sprianocommunication.com